China’s CanSino vaccine is 74.8% effective in preventing COVID-19, Special Assistant to the PM for Health Dr Faisal Sultan said late Monday.
Dr Sultan said that the vaccine proved 100% effective at preventing severe diseases in the group of volunteers from Pakistan. He congratulated the health workers for conducting successful trials across the country.
In the Pakistani subset, efficacy at preventing symptomatic cases is 74.8% & 100% at preventing severe disease.
The IDMC didn’t report any serious safety concerns. Data incld 30,000 participants & 101 virologically confmd COVID cases
Well done Pak team for conducting this trial
— Faisal Sultan (@fslsltn) February 8, 2021
A multi-country analysis by the Independent Data Monitoring Committee shows 65.7% efficacy for symptomatic cases and 90.98% for the severe ones. No serious safety concerns were reported.
Clinical trial data (phase-3) of a one-dose Ad5-nCoV vaccine for Covid (Cansino Bio) received. Interim analysis by the Independent Data Monitoring Committee shows 65.7% efficacy at preventing symptomatic cases and 90.98% at preventing severe disease (multicountry analysis).
— Faisal Sultan (@fslsltn) February 8, 2021
One of CanSino’s biggest trials is being conducted in Pakistan, which will also receive 20 million doses, Bloomberg reported Monday.
The vaccine is developed by the German BioNTech in collaboration with the Chinese military. Its final stage trials involved 30,000 volunteers.
A vaccine must have at least 50% protection rate to be considered effective, according to the world’s leading regulators and the World Health Organisation.
A nationwide immunisation campaign against coronavirus began in Pakistan on February 3. Thousands of frontline health workers from both public and private sectors are being inoculated first.
The federal government has distributed the Chinese-made coronavirus vaccines among Sindh, Punjab, Khyber Pakhtunkhwa, and Balochistan. Sindh received 84,000 doses of the vaccine, Punjab 70,000, KP 65,000, and Balochistan 10,300 doses.
from SAMAA https://ift.tt/3rGHWwh
No comments:
Post a Comment